Zacks Investment Research upgraded shares of Allakos (NASDAQ:ALLK) from a hold rating to a buy rating in a research note published on Monday. Zacks Investment Research currently has $38.00 price objective on the stock.
According to Zacks, “Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States. “
ALLK has been the topic of a number of other reports. William Blair started coverage on shares of Allakos in a research note on Monday, August 13th. They issued an outperform rating on the stock. Jefferies Financial Group started coverage on shares of Allakos in a research note on Monday, August 13th. They issued a buy rating and a $53.00 price objective on the stock. Finally, Goldman Sachs Group started coverage on shares of Allakos in a research note on Monday, August 13th. They issued a neutral rating and a $31.00 price objective on the stock.
Shares of NASDAQ:ALLK opened at $40.10 on Monday. Allakos has a 1 year low of $26.00 and a 1 year high of $49.10.
Allakos (NASDAQ:ALLK) last announced its quarterly earnings data on Wednesday, August 29th. The company reported ($4.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($3.90). On average, equities research analysts expect that Allakos will post -1.07 EPS for the current year.
In related news, major shareholder Venture Fund (Ohi Rivervest II bought 111,111 shares of the firm’s stock in a transaction on Monday, July 23rd. The shares were purchased at an average price of $18.00 per share, with a total value of $1,999,998.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Janney bought 250,000 shares of the firm’s stock in a transaction on Monday, July 23rd. The shares were bought at an average cost of $18.00 per share, for a total transaction of $4,500,000.00. The disclosure for this purchase can be found here.
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Featured Story: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.